FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials,  today announced preclinical data from its CYPS317 program for Psoriasis presented at the Society for Investigative Dermatology 2026 Annual Meeting, held May 13-15, 2026, in Chicago, Illinois. 

In an imiquimod-induced psoriasis mouse model, both HDF spheroids and single-cell HDF preparations reduced disease severity; however, spheroids provided a more favorable systemic safety profile by avoiding the innate immune activation observed with single-cell delivery, an important distinction for a cell-based therapy intended for systemic administration.

In a chronic-relapsing psoriasis model, booster dosing of HDF spheroids sustained therapeutic efficacy and prevented splenomegaly, a marker of systemic immune burden. Additionally, CYPS317 demonstrated significant reductions in PASI scores, normalization of monocyte-to-lymphocyte ratios, and reduced splenic immune cell accumulation. Histological analyses confirmed that spheroid-treated animals were protected against epidermal thickening and immune cell infiltration, two hallmarks of active psoriatic disease. Cytokine profiling across disease stages demonstrated that single and multiple doses of HDF spheroids differentially regulated key inflammatory mediators, consistent with targeted immunomodulation rather than broad immune suppression.